Program
Anti-c-Met Antibody-drug Conjugate YL211
Also written as “YL211”, “YL211+Pembrolizumab” and “YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)”.
In hoffmann la roche’s pipeline, cMET ADC
. Its studies are led by MediLink Therapeutics (Suzhou).
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MediLink Therapeutics (Suzhou) | 11 open or running | phase 1since Mar 26, 2024 | Mar 26, 2024 | Jun 30, 2031phase 1 · NCT06384352 |
- Named in hoffmann la roche’s own pipeline as
RG6648 cMET ADC (MediLink)
, phase 1, as of Oct 22, 2026 (source).
Also a collaborator on its studies: Hoffmann-La Roche.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 26, 2024First study: phase 1 study in Advanced Solid TumorsFirst studyNCT06384352 · 500 planned · United States, Australia, Canada and more
Ahead
- Jun 30, 2031Primary completion: phase 1 study in Advanced Solid TumorsNCT06384352
TargetBeta
“cMET ADC”the company's pipeline, read by Claude · source
Other programs on MET
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Crizotinibrule | Pfizer | phase 4 | 31 |
| telisotuzumab adizutecan | AbbVie | phase 3 | 18 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| amivantamabrule | Johnson & Johnson | phase 3 | 16 |
| vebreltinibrule | beijing-pearl-biotechnology-limited-liability-company | phase 3 | 9 |
| glumetinibrule | Haihe Biopharma | phase 3 | 8 |
| vilzemetkib | Sino Biopharmaceutical | phase 3 | 8 |
| dalmelitinib | Hansoh Pharmaceutical Group | phase 3 | 7 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| SHR-1826 | Jiangsu HengRui Medicine | phase 2 | 7 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06384352Advanced Solid Tumors · United States, Australia, Canada and more | 1 | Recruiting | Jun 30, 2031 | 500 |
How it is read
Names in the registry
- “YL211”, 1 entry
- “YL211+Pembrolizumab”, 1 entry
- “YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)”, 1 entry
Codes read as this program: YL211.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.